Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics is viewed positively because its lead asset Lumvoa (veligrotug) has generated encouraging phase III data in active and chronic TED, meeting primary and secondary endpoints with proptosis and CAS improvements that appear par with teprotumumab while also offering a potentially differentiated diplopia benefit and fewer doses that improve real-world practicality. The launch commentary is also constructive, with 3/6 KOLs already writing at least 1 Rx, 2/6 planning near-term prescribing, 2/6 already infusing patients, and 95% of ~2,000 core prescribers contacted showing positive feedback, suggesting meaningful physician engagement and early demand despite access headwinds such as prior authorizations and the absence of a permanent J-code expected in 1Q27. The broader investment case is strengthened by a large TED market already validated by Tepezza’s ~\$2B run-rate since 2022, a new-start-heavy market structure that supports share gains, and a pipeline that extends into subcutaneous elegrobart plus earlier-stage FcRn assets, giving Viridian multiple shots to expand penetration and sustain long-term growth.

Viridian Therapeutics is viewed negatively because its TED franchise remains highly concentrated in a single indication where anti-IGF-1R therapy already carries meaningful adoption barriers, including hearing loss, ~20% relapse after Tepezza, and no reliable relapse predictor or maintenance paradigm, which limits confidence in durable uptake. Even though Lumvoa/veligrotug has shown differentiated efficacy and dosing convenience, the company still faces material execution and commercialization risk, with management indicating market access could take 6–9 months, minimal 2026 revenue of about $10m, and more meaningful revenue only beginning in 2H27. The bearish case is reinforced by regulatory and competitive uncertainty around approval and differentiation, alongside a downside scenario in which a failure of veligrotug could leave VRDN trading near its net cash position with minimal pipeline value at $14/sh.